Project Number: 1R43CA228746-01A1
Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER
Project Number: 1R43CA228746-01A1
Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER
New York City, New York Jun 29, 2021 (Issuewire.com) – EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, […]
https://www.issuewire.com/manhattan-biosolutions-inc-selected-to-be-featured-in-new-york-pavilion-at-bio-international-convention-1766550010501619 New York City, New York May 22, 2023 (Issuewire.com) – Manhattan BioSolutions, Inc. (“Manhattan Bio”), an emerging biotechnology company developing new classes of […]
New York, NY, May 27, 2020 – Manhattan BioSolutions, Inc. (MBS), a biotechnology company focused on the discovery of the next-generation therapies […]